ArticleJournal of contemporary brachytherapy2021
High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases.
Article in Journal of contemporary brachytherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities.Journal of surgical oncology · 2022Pooled it
- Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach.Therapeutic advances in medical oncology · 2025Review
- Harnessing the synergy of contact brachytherapy and immune checkpoint inhibitors in advanced melanoma: first reported case series.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to present a case of complete clinical response of renal clear cell carcinoma cutaneous metastases after high-dose-rate surface brachytherapy (HDR sBT). MATERIAL AND
methodsAn 81-year-old female diagnosed with stage IV clear cell renal carcinoma reported to our center with painful relapse of two cutaneous metastases after a previous metastasectomy. The patient was disqualified from systemic therapy due to comorbidities, and qualified to attempt a treatment using HDR sBT. The unit equipped with an iridium-192 source was used to deliver 36 Gy/6 Gy in 6 fractions twice weekly. Overall treatment time was 18 days.
resultsTwo weeks after HDR sBT, complete response was observed in one irradiated location, while the partial response was observed in the latter. EORTC grade 1 skin toxicity was reported in both irradiated fields. Three and five months after the treatment, the patient presented complete response and pain relief in both locations with no signs of relapse. The patient remained in palliative care and died seven months after the treatment due to sudden cardiac death.
conclusionsHDR sBT can be a valuable treatment option for cutaneous metastatic renal cell carcinoma, especially for patients with significant comorbidities. The treatment provided was associated with low toxicity and excellent clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.